Category: Oncotarget

Oncotarget News

Figure 9: One-step SARS-COv2 genome assembly in yeast S. cerevisiae using transformation-associated recombination (TAR) in yeast

Transformation-associated Recombination (TAR) Cloning and Its Applications

January 8, 2024

TAR cloning is used to genetically engineer synthetic viruses with novel properties that may be used for the development of new vaccines.”BUFFALO, NY- January 8, 2024 – A new review... read more

Oncotarget

Therapeutically Harnessing Cancer Stem Cell-derived Exosomes

January 3, 2024

recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.”BUFFALO, NY- January 3, 2024 – A new editorial paper was published in Oncotarget's Volume 14... read more

Figure 9: Effect of GFH009 treatment on CDK9-dependent protein expression in vivo.

Oncotarget

GFH009: A Potent and Highly Selective CDK9 Inhibitor for the Treatment of Hematologic Malignancies

December 27, 2023

the results of this preclinical investigation program suggest that induction of apoptosis is a key component of GFH009’s anti-tumor mechanism of action [...]”BUFFALO, NY- December 27, 2023 – A new... read more

Oncotarget

Management of Refractory or Relapsed Classic Hodgkin Lymphoma in Brazil

December 20, 2023

The management of patients with refractory or relapsed CHL in the Brazilian healthcare setting is constrained [...]”BUFFALO, NY- December 20, 2023 – A new review paper was published in Oncotarget's Volume... read more

Figure 1: Trends in the annual numbers of publications.

Oncotarget

Melatonin and Carcinogenesis in Mice

December 18, 2023

murine models proved to be valuable and, in some cases, indispensable for advancing melatonin applications in oncology [...].”BUFFALO, NY- December 18, 2023 – A new research perspective was published in Oncotarget's... read more

Oncotarget

Behind the Study: Osteopontin Induces Mitochondrial Biogenesis in Deadherent Cancer Cells

December 14, 2023

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, James L. Winkle College of Pharmacy, details a research paper he co-authored that was published by Oncotarget in... read more

Oncotarget

Cytostatic Persister Cancer Cells: Therapeutic Opportunities and Challenges

December 13, 2023

we anticipate that heterogeneous persister populations are inevitable in [cancer] treatment.”BUFFALO, NY- December 13, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on December 1, 2023,... read more

Oncotarget

Risk Factors for Long-Term Arm Morbidities Following Breast Cancer Treatments: A Systematic Review

December 11, 2023

This review revealed 29 primary risk factors associated with arm morbidity after breast cancer treatment.”BUFFALO, NY- December 11, 2023 – A new review paper was published in Oncotarget's Volume 14... read more

Figure 3: Patient examples of inverse correlation of BCMA and FLC changes during course of therapy.

Oncotarget

BCMA+ EV Levels Correlate With Myeloma Response to Belantamab-Mafodotin

December 6, 2023

Measurement of BCMA-EV can thus help in identifying resistance mechanisms and side effects of BCMA targeted therapies in future studies.”BUFFALO, NY- December 6, 2023 – A new research paper was... read more

Figure 5: The mediators of mitochondrial biogenesis are required for cancer spread. "Osteopontin induces mitochondrial biogenesis in deadherent cancer cells"

Oncotarget

Osteopontin Induces Mitochondrial Biogenesis in Deadherent Cancer Cells

December 4, 2023

Here, we study the induction of mitochondrial biogenesis by Osteopontin variants in deadherent breast tumor cells.”BUFFALO, NY- December 4, 2023 – A new research paper was published in Oncotarget's Volume... read more